The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

This approval marks a milestone for high-risk sMM patients, but analyst Biswajit Podder notes that there are caveats to its ...

The U.S. Food and Drug Administration approved Johnson & Johnson’s drug Darzalex Faspro as the first treatment for adults with high-risk smoldering multiple myeloma, a precursor to the blood cancer.

In patients with symptomatic multiple myeloma, renal impairment leading to acute kidney injury (AKI) is a common complication ...

Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug ...